BMY

Bristol-Myers Squibb Co.

64.41

USD

-0.28

-0.43%

Sep 09, 15:59 UTC -4

Closed

After-Market

64.49

+0.08

+0.12%

Bristol-Myers Squibb Co. Profile

About

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.

Info & Links

CEO

Christopher Boerner

Headquarters

ROUTE 206 AND PROVINCE LINE ROAD
PRINCETON, NJ 08543, UNITED STATES

Auditor

DELOITTE & TOUCHE LLP

Share holders

28,145

Employees

32,500

Bristol-Myers Squibb Co. Statistics

Valuation Measures

Market Capitalization²

131.73B

Enterprise Value

166.13B

Enterprise Value/EBITDA(ttm)

11.01

Price to Earnings Ratio(ttm)

10.26

Price to Sales(ttm)

2.78

Price to Book(mrq)

6.12

Price to Cash(ytd)

8.22

Profitability

Gross Margin(ttm)

70.16%

Operating Margin(ttm)

27.04%

Profit Margin(ttm)

18.89%

Return on Equity(ttm)

66.90%

Return on Invested Capital(ttm)

14.70%

Return on Assets(ttm)

14.74%

Income Statement

Revenue(ttm)

49.19B

Revenue Per Share(ttm)

24.08

Gross Profit(ttm)

34.51B

EBITDA(ttm)³

15.09B

Net Income Available to Common(ttm)

9.28B

Diluted EPS(ttm)

4.54

Share Statistics

Beta (5Y Monthly)

0.23

52-Week Change

37.86%

S&P 500 52-Week Change

18.41%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

2.04B

Dividend Yield

3.77%

Float⁴

2.04B

% Held by Insiders

0.05%

% Held by Institutions

76.41%

Balance Sheet

Total Cash(mrq)

11.07B

Total Cash Per Share(mrq)

5.42

Total Debt(mrq)

43.12B

Total Debt/Equity(mrq)

193.20%

Current Ratio(mrq)

1.53%

Quick Ratio(mrq)

1.38%

Book Value Per Share(mrq)

10.92

Cash Flow

Operating Cash Flow Per Share(ytd)

2.20

Free Cash Flow(ytd)

3.85B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

BMY